{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:29:56Z","timestamp":1760236196077,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Hypersensitivity reactions (HSR)s to platinum agents are increasing in frequency, due to their extensive use and repeated exposures in patients with increased life expectancy. The aims of our study are to analyze the frequency of both type I and type IV HSRs in patients with gynecological cancer treated with (CBDCA) carboplatin and\/or (CDDP) cisplatin, to evaluate the role of skin tests in the diagnosis and prevention of HSRs. Methods: From 2011 to 2018, we evaluated 124 consecutive female patients previously treated with CBDCA and\/or CDDP for gynecological cancer. All patients, including those with and without HSR to previous platinum-based therapy, underwent in-vivo skin tests for platinum agents before starting the second or more therapeutic lines. To reduce the risk of false negative results, patients with a negative skin test at the first evaluation were re-tested after 3 weeks from the platinum re-exposure. Results: Among the 124 patients evaluated, 58 (47%) experienced HSRs to at least one platinum agent: 35% were to CBDCA, 5% to CDDP, 7% to both. Fifty-six of the 58 HSRs were classified as immediate and two delayed. Skin tests confirmed an IgE-dependent mechanism in 67% of patients with immediate-HSRs to CBDCA and identified a cross-reactivity between platinum agents in 18% of patients. Moreover, among those who had never developed an HSRs during platinum-based therapy, in-vivo skin tests identified 12% of sensitized patients. Conclusions: On the basis of our findings, skin test for platinum agents is a simple and sensitive tool for the diagnosis and prevention of HSRs to CBDCA and\/or CDDP and can be useful for detecting possible cross-reactivity among platinum agents.<\/jats:p>","DOI":"10.3390\/cancers13215468","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:47:38Z","timestamp":1635767258000},"page":"5468","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Ilaria","family":"Puxeddu","sequence":"first","affiliation":[{"name":"Immunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Petrelli","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Guerrieri","sequence":"additional","affiliation":[{"name":"Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Cosio","sequence":"additional","affiliation":[{"name":"Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Del Corso","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Rocchi","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9274-2313","authenticated-orcid":false,"given":"Maria Laura","family":"Manca","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Migliorini","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angiolo","family":"Gadducci","sequence":"additional","affiliation":[{"name":"Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/ijgc-00009577-200501000-00003","article-title":"Carboplatin hypersensitivity","volume":"15","author":"Sliesoraitis","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2013.06.002","article-title":"Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: Cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy","volume":"1","author":"Caiado","year":"2013","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jaip.2019.01.057","article-title":"Low cross-reactivity between cisplatin and other platinum salts","volume":"7","author":"Pasteur","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1525-1438.2007.01063.x","article-title":"Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11882-015-0515-3","article-title":"Presentation and diagnosis of hypersensitivity to platinum drugs","volume":"15","author":"Caiado","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2013.389","article-title":"Deleterious BRCA1\/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions","volume":"109","author":"Moon","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jjco\/hys006","article-title":"An experimental biological test to diagnose hypersensitivity reactions to carboplatin: New horizons for an old problem","volume":"42","author":"Pagani","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","article-title":"Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy","volume":"19","author":"Zanotti","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2006.11.640","article-title":"Diagnostic and predictive value of skin testing in platinum salt hypersensitivity","volume":"119","author":"Jolimoy","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11882-014-0451-7","article-title":"Diagnostic tools for hypersensitivity to platinum drugs and taxanes: Skin testing, specific IgE, and mast cell\/basophil mediators","volume":"14","author":"Caiado","year":"2014","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaip.2015.07.003","article-title":"Skin testing in the evaluation and management of carboplatin-related hypersensitivity reactions","volume":"3","author":"Lax","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2003.05.539","article-title":"Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","article-title":"A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions","volume":"129","author":"Patil","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.anai.2015.07.017","article-title":"Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: Repeat skin testing to identify drug allergy","volume":"115","author":"Wang","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdq577","article-title":"Survival in epithelial ovarian cancer: A multivariate analysis incorporating BRCA mutation status and platinum sensitivity","volume":"22","author":"Gallagher","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"ENDA\/EAACI Drug Allergy Interest Group. Skin test concentrations for systemically administered drugs\u2014An ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ygyno.2018.10.037","article-title":"Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions","volume":"152","author":"Vetter","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0090-8258(03)00178-1","article-title":"Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity","volume":"89","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2016.10.023","article-title":"Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin","volume":"144","author":"Bergamini","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tate, S., Nishikimi, K., Matsuoka, A., Otsuka, S., and Shozu, M. (2021). Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin. Cancers, 13.","DOI":"10.3390\/cancers13040640"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ygyno.2017.03.015","article-title":"Outpatient desensitization in selected patients with platinum hypersensitivity reactions","volume":"145","author":"Vetter","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2016.09.027","article-title":"Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study","volume":"144","author":"Altwerger","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s10147-021-01935-7","article-title":"4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: A prospective study","volume":"26","author":"Nishimura","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_30","unstructured":"Coutinho, I.A., Costa Sousa, F., Cunha, F., Frutuoso, C., Ribeiro, C., Loureiro, C., \u00c1guas, F., and Todo Bom, A. (2021). Key elements in hypersensitivity reactions to chemotherapy: Experience with rapid drug desensitization in gynaecological cancer in a tertiary hospital. Eur. Ann. Allergy Clin. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:38Z","timestamp":1760167418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":30,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215468"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215468","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,10,30]]}}}